Revenue Growth Amidst Margin Challenges

Jubilant Pharmova finished fiscal year 2026 with a significant 14% revenue increase, reaching ₹8,280 crore. The growth was primarily fueled by strong performance in its contract drug manufacturing and allergy immunotherapy businesses. However, earnings before interest, taxes, depreciation, and amortization (EBITDA) grew by 8% to ₹1,326 crore, falling behind revenue growth and signaling a compression in profit margins.

Sterile Injectables Lead the Charge

The contract drug manufacturing (CDMO) segment, particularly sterile injectables, was a key driver. Revenue in this area surged 38% to ₹1,755 crore. This boost came from the activation of a third fill-and-finish line at the Spokane, Washington facility, which secured a major contract for an oncology product. The Spokane site experienced substantial growth, with revenue up 48% and EBITDA up 59%.

Margin Squeeze and Recovery Plans

Despite the strong revenue performance, Jubilant Pharmova's EBITDA margins narrowed by 99 basis points to 15.9% for the fiscal year. This reduction was mainly due to a temporary shutdown of its Montreal plant, which produces SPECT radiopharmaceutical products, following observations from the FDA. While commercial batch production is set to restart soon after completing necessary media fills, management expects margins to improve in the second half of FY27. As of March 2026, the company's net debt to EBITDA ratio was 1.3x, a slight rise from the previous year. The stock closed down 0.52% at ₹1,006.35 on the NSE on Friday.

Radiopharmacy Network Expansion

The radiopharmacy segment contributed 9% to revenue, totaling ₹2,512 crore. Key initiatives include expanding distribution for PYLARIFY and starting supply of Pluvito. A $50 million investment is planned to enhance its U.S. PET radiopharmacy network. The company is also benefiting from U.S. pharmaceutical firms seeking domestic manufacturing capacity due to new tariffs, increasing the utilization of its Spokane facility. A fourth sterile fill-and-finish line is in development, with revenue from technology transfer anticipated by Q4 FY27.

Competitive Landscape and Valuation

Jubilant Pharmova competes with companies like Marksans Pharma, Strides Pharma Science, and Zydus Lifesciences. It holds a strong position in radiopharmaceuticals, ranking as the third-largest manufacturer in the U.S. and operating the second-largest network with 46 radiopharmacies. However, it faces competition from Lantheus and Curium in diagnostics and cardiac imaging, and Telix's expansion into theranostics could affect Jubilant's development timelines. The company's P/E ratio of approximately 37.3 is below the sector average of 71.81, suggesting a potentially more favorable valuation. Despite this, earnings have declined by 4.6% annually over the last five years, a point of concern. Jubilant Pharmova has a market capitalization of about ₹16,037 crore. Analyst reports from late 2025 noted an improved EBITDA margin of 19.5%, attributed to its high-margin specialty product mix. The company's dividend yield is 0.49%, which is not well supported by its free cash flows.

Potential Risks and Concerns

The contraction in EBITDA margins due to the Montreal facility shutdown highlights a recurring risk for Jubilant Pharmova. Dependence on specific plants for key products like SPECT radiopharmaceuticals means operational issues can significantly impact profitability. The increase in the net debt to EBITDA ratio to 1.3x also indicates rising leverage, which could be problematic if earnings do not improve as expected. An impairment of ₹8.7 crore in an associate investment during Q4 FY26 was also reported as an exceptional item. The consistent decline in earnings over the past five years is a notable risk. Furthermore, the sustainability of the dividend is questionable given that it is not adequately covered by free cash flows.

Future Prospects

Management expects EBITDA margins to recover in the second half of FY27, following the stabilization of production at the Montreal facility. The company is also investing in its PET radiopharmacy network and a fourth sterile fill-and-finish line, which are expected to drive future revenue. Analyst forecasts predict earnings growth of 27.61% annually, potentially reversing the recent decline and boosting future profitability.